

1                   **Bifidobacteria reduce gliadin-induced toxicity**

2  
3                   Laparra J.M. and Sanz Y.\*

4    Microbial Ecophysiology and Nutrition Group. Instituto de Agroquímica y Tecnología  
5                   de Alimentos (CSIC), Apartado 73, 46100, Burjassot (Valencia), Spain.

6  
7  
8  
9  
10 **Running title:** Bifidobacteria attenuate gliadin-induced inflammation

11  
12 **\*Corresponding author:** Yolanda Sanz

13                   E-mail: yolsanz@iata.csic.es

14                   Telephone: (+34) 963 900 022

15                   Fax: (+34) 963 636 301

1 **ABSTRACT**

2 Celiac disease (CD) is a chronic enteropathy triggered by intake of gliadin, the toxic  
3 component of gluten. This study aims at evaluating the capacity of different  
4 *Bifidobacterium* strains to counteract the inflammatory effects of gliadin-derived  
5 peptides in intestinal epithelial (Caco-2) cells. A commercial extract of several gliadin  
6 (Gld) types ( $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\omega$ ) was subjected to *in vitro* gastrointestinal digestion (pepsin at pH  
7 3, pancreatin-bile at pH 6), inoculated or not with cell suspensions ( $10^8$  colony forming  
8 units/ml) of either *B. animalis* IATA-A2, *B. longum* IATA-ES1, or *B. bifidum* IATA-  
9 ES2, in a bicameral system. The generated gliadin-derived peptides were identified by  
10 reverse phase-HPLC-ESI-Ms/Ms. Caco-2 cell cultures were exposed to the different  
11 gliadin peptide digestions (0.25 mg protein/mL), and the mRNA expression of NF- $\kappa$ B,  
12 TNF- $\alpha$ , and chemokine CXCR3 receptor were analysed by semi-quantitative reverse  
13 transcription-polymerase chain reaction (RT-PCR) in stimulated cells. The production  
14 of the pro-inflammatory markers NF- $\kappa$ B p50, TNF- $\alpha$ , and IL-1 $\beta$  by Caco-2 cells was  
15 also determined by ELISA. The peptides from gliadin digestions inoculated with  
16 bifidobacteria did not exhibit the toxic amino acid sequences identified in those non  
17 inoculated ( $\alpha/\beta$ -Gld [158-164] and  $\alpha/\beta$ -Gld [122-141]). The RT-PCR analysis  
18 evidenced a down-regulation in mRNA expression of pro-inflammatory biomarkers.  
19 Consistent with these results the production of NF- $\kappa$ B, TNF $\alpha$  and IL-1 $\beta$  was reduced  
20 (18.2-22.4%, 28.0-64.8% and abolished, respectively) in cell cultures exposed to gliadin  
21 digestions inoculated with bifidobacteria. Therefore, bifidobacteria change the gliadin-  
22 derived peptide pattern and, thereby, attenuate their pro-inflammatory effects on Caco-2  
23 cells.

24 **Keywords:** Celiac disease, gliadin, *Bifidobacterium*, Caco-2, cytokines.

## 1 INTRODUCTION

2 Celiac disease (CD) is an autoimmune enteropathy caused by a permanent  
3 intolerance to cereal gluten proteins. Gliadins ( $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\omega$  types), are the main toxic  
4 components of gluten. In CD patients, gliadin-derived peptides generally induce  
5 intestinal symptoms and severe mucosal damage due to an abnormal immune response  
6 to the incomplete digested gliadin peptides by human digestive enzymes [Wieser and  
7 Koehler, 2008]. Currently, the only available therapy for CD patients is the adherence to  
8 a strict life-long gluten free diet; however, the compliance with this dietary  
9 recommendation is complex and other alternative strategies are needed [Sanz, 2009].

10 It has been reported that gliadin-derived peptides stimulate not only  
11 immunocompetent cells [Thomas et al., 2006], but also enterocytes [Lammers et al.,  
12 2008] via the myeloid differentiation factor (MyD88) and the chemokine receptor  
13 CXCR3 associated to Toll-like receptor signaling pathways. Different gliadin-derived  
14 peptides with specific amino acid sequences have proven to trigger pro-inflammatory  
15 cell responses. These involve activation of the nuclear factor kappa-B (NF- $\kappa$ B) in small  
16 intestinal mucosa of celiac patients [Chiara et al., 2003] and increased expression of  
17 pro-inflammatory cytokines related to the innate immune response, such as tumor  
18 necrosis factor  $\alpha$  (TNF $\alpha$ ) [Nilsen et al., 19989] and interleukine (IL) 1 $\beta$  [Beckett et al.,  
19 1999].

20 Scientific evidence supports the hypothesis that not only genetic, but also  
21 environmental factors other than gluten intake may play an important role in CD  
22 pathogenesis [Fergusson et al., 2007]. Imbalances in the gut microbiota of CD patients  
23 have been previously reported [Nadal et al., 2007; Sanz et al., 2007]. In particular, the  
24 abundance of *Bifidobacterium* species tended to be reduced in feces and biopsies of CD  
25 patients [Nadal et al., 2007]. *Bifidobacterium* species are thought to positively influence  
26 the host-immune response(s) in a species and strain-specific manner [Young et al.,  
27 2004; Roselli et al., 2006; Medina et al., 2008]. Specific *Bifidobacterium* strains have  
28 been shown to counteract the pro-inflammatory response induced by the fecal  
29 microbiota of CD patients in peripheral blood mononuclear cells [Medina et al., 2008].  
30 A *Bifidobacterium animalis* subsp. *lactis* strain was also shown to inhibit the increased  
31 epithelial permeability induced by gliadin [Lindfors et al., 2008].

32 The association of alterations in the gut microbiota composition with CD, and the  
33 recognized roles played by probiotic bacteria on host's health have led to propose the

1 use of probiotics as an additional nutritional strategy to improve the quality of life of  
2 CD patients [Sanz, 2009]. Increasing efforts are being made to elucidate the interactions  
3 among bacteria, the enterocytes and the immune system [Troncone et al., 2008]. In this  
4 context, diverse *in vitro* models have been designed to evaluate and/or predict the effect  
5 that potentially probiotic bacterial strains might exert to reduce the toxicity and  
6 inflammatory response(s) at intestinal level. The use of these models is critical in view  
7 to developing future clinical trials in humans.

8 The objectives of this study have been to identify the effects of bifidobacteria on the  
9 peptide sequences generated during the gastrointestinal digestion of gliadins and to  
10 compare their toxicity and pro-inflammatory effects on Caco-2 cell cultures, used as  
11 model of intestinal epithelia.

## 13 MATERIAL AND METHODS

14 **Bacterial cultures.** *Bifidobacterium* strains (*B. bifidum* IATA-ES2 [CECT 7365, *B.*  
15 *longum* IATA-ES1 [CECT 7347], and *B. animalis* IATA-A2) were isolated from faeces  
16 of healthy infants as described elsewhere (Medina et al., 2008). The bacterial strains  
17 were grown in Man-Rogosa-Sharpe broth and agar (Scharlau, Barcelona, Spain)  
18 supplemented with 0.05% (w/v) cysteine (Sigma, St. Louis, MO), and incubated at 37°C  
19 under anaerobic conditions (AnaeroGen; Oxoid, Basingstoke, UK) for 24h.

20 **Cell culture conditions.** The human colon carcinoma Caco-2 cell line was obtained  
21 from the American Type Culture Collection (Rockville, MD, USA) at passage 17 and  
22 used in experiments at passage 25-33. Caco-2 cells were grown in Dulbecco's Modified  
23 Eagle Medium (DMEM Glutamax, Gibco) containing 4.5 g L<sup>-1</sup> glucose, 25 mM HEPES  
24 buffer, and 10% fetal bovine serum (Gibco). The cells were maintained at 37°C in 5%  
25 CO<sub>2</sub>, 95% air and the culture medium was changed every 2 days [Laparra et al., 2008].

26 For experimental studies Caco-2 were seeded at a density of 50,000 cells cm<sup>-2</sup> onto  
27 6 well plates (Costar, Cambridge, MA, USA). Cell cultures were grown with DMEM,  
28 and culture media was changed every two days. Experiments were performed 5 days  
29 post seeding.

30 ***In vitro* digestion of gliadins.** The gastrointestinal digestion process was simulated  
31 as previously described [Laparra et al., 2009], using porcine pepsin (P-7000, Sigma)  
32 (800-2500 units/mg protein), pancreatin (P1750, Sigma) (activity, 4×USP  
33 specifications) and bile (B3883, Sigma). Aliquots (150 mg) of a commercially available  
34 extract of gliadin (G3375, Sigma) were weighted in centrifuge tubes (50 ml), and 3 ml

1 of a saline solution (140 mM NaCl, 5 mM KCl adjusted a pH 3) was added to each  
2 sample. The mixture was immersed in a water bath (60 °C) for 30 minutes with gentle  
3 agitation. Briefly, gastric and intestinal digestions were conducted on a rocking platform  
4 shaker placed in an incubator (37°C/5% CO<sub>2</sub>/95% relative humidity). After the gastric  
5 digestion (pepsin in 0.1M HCl/pH 3/1h), the intestinal digestion (pancreatin-bile extract  
6 in 0.1 NaHCO<sub>3</sub>/pH 6.9-7/2h) was carried out in the upper chamber of a two-chamber  
7 system in 6-well plates. The upper chamber was formed by fitting the bottom of an  
8 appropriately sized Transwell insert ring (Corning) with a 15,000 molecular mass cut-  
9 off dialysis membrane (Spectra/Por 2.1, Spectrum Medical, Gardena, CA, USA).  
10 Aliquots (1.5 ml) of the intestinal digest, inoculated or not with bacterial cell  
11 suspensions (10<sup>8</sup> colony forming units [CFU]/ml), were loaded into the upper chambers  
12 and incubated for 2 h. Afterwards, the inserts were removed and an additional 1 mL of  
13 DMEM was added to each well. Cell cultures were returned to the incubator for  
14 additional 12 hours.

15 Total protein concentration in both dialyzates and retentates were determined using  
16 a Lowry method based commercial kit (TP0200, Sigma). After *in vitro* digestion,  
17 bacterial cell growth ability was confirmed by plate count and ranged between 10<sup>6</sup>-10<sup>7</sup>  
18 CFU/mL.

19 **Reverse phase-HPLC and tandem Mass spectrometry (Ms/Ms) analysis (RP-**  
20 **HPLC-ESI-Ms/Ms).** Aliquots (1 mL) of the dialyzates from the gliadin digestions,  
21 inoculated or not with *Bifidobacterium* strains, were filtered through a nylon  
22 membrane (13 mm 0.22 µm Millex GN, Millipore) before the analysis. The separation  
23 and identification of gliadin-derived peptides was performed on an Agilent HPLC  
24 system connected on line to an Esquire-LC electrospray system equipped with a  
25 quadrupole ion trap mass spectrometer (Bruker Daltonics, Billerica, MA). The HPLC  
26 system was equipped with a quaternary pump, an in line degasser, an automatic injector,  
27 and a variable wavelength absorbance detector set at 214 nm (1100 Series, Agilent  
28 Technologies, Waldbronn, Germany). The column used in these analyses was a  
29 BioBasic C18 5 µm 4.6x250 mm (Thermo, Waltham, MA, USA). The elution phases  
30 consisted of (A) Acetonitrile (ACN) 15% (v/v)/Trifluoroacetic acid (TFA) 0.1% (v/v),  
31 and (B) ACN 80% (v/v)/TFA 0.1% (v/v). Aliquots (100 µl equivalents to 116 µg  
32 protein) of the dialyzates resulting from digestions of the commercially available extract  
33 of gliadin types were injected in each analysis. The gradient program started with 95%  
34 of solvent A and 5% of solvent B, and changed linearly to reach 10% of solvent A and

1 90% of solvent B in 30 min. The column was cleaned with 90% of solvent B (5 min)  
2 and equilibrated with the initial conditions for 5 minutes. UV absorbance was recorded  
3 at 214 nm. Nitrogen was used as the nebulizing and drying gas, and the helium collision  
4 gas pressure was approximately  $5 \times 10^{-3}$  bar. The capillary was held at 4 kV. Mass  
5 spectra were recorded over the mass/charge ( $m/z$ ) range 100-3500. About 15 spectra  
6 were averaged in the Ms analyses and about five spectra in the Ms/Ms analyses. The  
7 signal threshold to perform auto-Ms/Ms analyses was 5000, and the precursor ions were  
8 isolated within a range of 4.0  $m/z$  and fragmented with a voltage ramp from 0.39 to 2.6  
9 V. The  $m/z$  spectral data were processed and transformed to spectra representing mass  
10 values using the program Data Analysis version 3.0 (Bruker Daltonics). BioTools  
11 version 2.1 (Bruker Daltonics) software was used to process the Ms/Ms spectra and to  
12 perform peptide sequencing by comparing with the different gliadin sequences  
13 (accession number:  $\alpha/\beta$ , AAZ94420;  $\gamma$ , AAQ63856;  $\omega$ , AAT74547). Three independent  
14 samples were injected in each analysis.

15 **Toxicity experiments.** Cell culture viabilities were determined by the toluylene red  
16 (3-amino-7-dimethylamino-2-methylphenazine hydrochloride) uptake assay  
17 [Borenfreund and Puerner, 1985]. The medium was removed and cells were washed  
18 twice with phosphate buffered saline (PBS, P4417, Sigma ). The uptake of toluylene red  
19 was measured using a commercial kit (No. 7H092, Sigma) at 540 nm with background  
20 subtraction at 690 nm. *In vitro* digests of bovine serum albumin (BSA) (0.25 mg  
21 protein/ml), were used as negative controls for toxicity. Control cells exposed to  
22 DMEM were analyzed with every assay.

23 **Analysis of pro-inflammatory markers.** To evaluate Nuclear factor kappa B (NF-  
24  $\kappa$ B) production the nuclear extract from Caco-2 cell cultures was obtained using a  
25 commercial kit according to the manufacturer's instructions (Active Motif, Cat. No.  
26 40010). Afterwards, the commercial TransAM<sup>TM</sup> kit (Active Motif, Cat. No. 43296)  
27 that contains antibodies directed against the NF- $\kappa$ B p65 subunit was used (TransAM<sup>TM</sup>,  
28 Cat. n°. 43296).

29 Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ , eBioscience; Cat. n°. 88-7346), and interleukine  
30 (IL)-1 $\beta$  (eBioscience; Cat. n°. 88-7010) were determined by ELISAs according to the  
31 instruction of the manufacturers. The results of the ELISA assay for NF- $\kappa$ B are  
32 expressed as percentage of the control, and TNF- $\alpha$  and IL-1 $\beta$  as pico-grams per mL  
33 (pg/ml) of media.

1        **Nucleic acid distribution in Caco-2 cultures.** Cell cycle analysis was performed  
2 by propidium iodide (PI) staining of DNA content in exposed cultures [Laparra et al.,  
3 2008]. Cells were washed with PBS and resuspended in 1 ml of lysis buffer [1 mg ml<sup>-1</sup>  
4 of trisodium citrate, 1 μl ml<sup>-1</sup> of sodium dodecyl sulphate (0.5% w/v), 0.05 mg ml<sup>-1</sup> PI,  
5 and 1 mg ml<sup>-1</sup> of RNase A (R4875, Sigma)]. After incubation overnight at 4°C, the  
6 released nuclei were re-suspended by agitation with a Pasteur pipette, and the  
7 fluorescence was analyzed by flow cytometry (Coulter, EPICS XL-MCL, USA) at  $\lambda_{exc}$   
8 = 536 nm and  $\lambda_{em}$  = 617 nm. Control cells exposed to DMEM were analyzed in each  
9 assay.

10        To evaluate total RNA distribution in cell cycle phases, simultaneous Hoechst  
11 33342 and pyronin Y staining was performed [Laparra et al., 2008]. Cells were  
12 harvested and resuspended in 700 μL of fixation solution (PBS:Ethanol, in 1:3 v/v ratio)  
13 for 5 minutes. Then, cells were centrifuged (1200 rpm/10 minutes) and resuspended in  
14 700 μl PBS containing Hoechst 33342 (30 μg/mL, final concentration) during 20  
15 minutes at room temperature. Afterwards, 700 μL PBS containing pyronin Y (2 μg/mL,  
16 final concentration) were added and incubated for 10 minutes at room temperature.  
17 Samples were analyzed on a Modular Flow Cytometer Cell Sorter (MoFlo Sorter,  
18 Dakocytomation, USA). Hoechst was excited with the UV line of an argon laser ( $\lambda_{exc}$ :  
19 346 nm -  $\lambda_{em}$ : 460 nm), and pyronin Y was excited at  $\lambda_{exc}$ : 555 nm and the fluorescence  
20 collected at  $\lambda_{em}$ : 580 nm.

21        **Analysis of the mRNA expression of proinflammatory biomarkers.** Total RNA  
22 was isolated from cell cultures (Qiagen, Cat. No 74104, USA) and first strand cDNAs  
23 were synthesized from 0.5 μg of total RNA. Polymerase chain reaction (PCR) was  
24 carried out with primers designed for TNFα (NM003842.4) (TNFα superfamily,  
25 member 2) (forward: 5'-AGG GTA CCA CAG AAA GAT GC-3'; reverse: 5'-GCA  
26 GAT GAG ACC CTT AGG TT-3'), NF-κB (NM003998.2) (forward: 5'-CTT CTC  
27 GGA GTC CCT CAC TG-3'; reverse: 5'-CCA ATA GCA GCT GGA AAA GC-3') and  
28 chemokine CXCR3 receptor (NM001142797.1) (forward: 5'-AAG AAT GCG AGA  
29 GAA GCA GC-3'; reverse: 5'-AAG AGG AGG CTG TAG AGG GC-3'). β-actin gene  
30 (NM000251.1) was used to normalize the results (forward: 5'-CTC TTC CAG CCT  
31 TCC TTC CT-3'; reverse: 5'-TAG AGC CAC CAA TCC ACA CA-3'). Amplifications  
32 of the TNFα, NF-κB and β-actin genes were performed in 35 cycles, which consisted of  
33 a first cDNA synthesis stage (45 °C, 1 h), AMV-reverse transcriptase (RT) inactivation

1 (95 °C, 2 min), denaturation (94 °C, 30 s), annealing (60 °C, 1 min), and extension (78  
2 °C, 2 min). RT-PCR products were separated by electrophoresis on a 1% agarose gel,  
3 stained with ethidium bromide, and quantified using a Image Gauge version 4.0 (Media  
4 Cybernetics, LP).

5 **Statistical analysis.** Each of the experiments were conducted in triplicate during  
6 two different days. One-way analysis of variance (ANOVA) and the Tukey *post hoc* test  
7 were applied [Box et al., 1978]. Statistical significance was established at  $p < 0.05$  for all  
8 comparisons. SPSS v.15 software (SPSS Inc., Chicago, IL, USA) was used for the  
9 statistical analysis.

## 12 RESULTS

13 **Gliadin-derived peptides.** The total protein content of the dialyzates from *in vitro*  
14 gliadin digestions without bifidobacteria constituted up to  $37.8 \pm 3.8\%$  of the protein  
15 content loaded in the upper chamber of the *in vitro* system. Only samples inoculated  
16 with *B. longum* IATA-ES1 produced a statistically significant ( $p < 0.05$ ) reduction (by  
17  $5.3 \pm 0.9\%$ ) in the dialyzable total protein content, suggesting a change in the degree of  
18 gliadin peptide hydrolysis.

19 The amino acid sequences of gliadin-derived peptides present in the dialyzates and  
20 generated in the presence or absence of bifidobacteria, were analyzed by RP-HPLC-  
21 ESI-MS/MS (**Table 1**). Different peptide patterns were detected in samples inoculated  
22 with bifidobacteria compared to those non-inoculated. Most peptides generated in  
23 samples inoculated with bifidobacteria showed lower molecular mass than those  
24 generated in non inoculated samples (~2500 Da) during intestinal digestion.

25 **Toxicity of gliadin digests.** The cytotoxic effect of proteolytic resistant gliadin-  
26 derived peptides was evaluated by using the neutral red uptake assay, which is based on  
27 the activation of endosomal/lysosomal activities [Borenfreund and Puerner, 1985]  
28 (**Figure 1**). The peptides from samples non-inoculated with bifidobacteria and from  
29 those inoculated with *B. animalis* and *B. bifidum* were cytotoxic for intestinal epithelial  
30 cells, as concluded from the decreased neutral red uptake percentages (by 5%)  
31 compared to the controls. In contrast, digestions inoculated with *B. longum* produced  
32 higher neutral red uptake percentages, which reflect an activation of  
33 endosomal/lysosomal activities and absence of toxicity.

1 None of the dialyzates from the different digestions assayed caused alterations in  
2 cell cycle phases population compared to the controls (sub-G1,  $6.58 \pm 2.43$ ; G0/G1,  
3  $63.51 \pm 1.02$ ; S,  $12.56 \pm 1.37$ ; G2/M,  $14.23 \pm 2.87$ ). Regarding total RNA content in  
4 cycle phases, only cell cultures (G1,  $70.4 \pm 0.1\%$ ; G2,  $14.6 \pm 4.6\%$ ) exposed to digests  
5 from gliadins and with those (G1,  $70.3 \pm 3.7\%$ ; G2,  $19.1 \pm 5.5\%$ ) digests inoculated  
6 with *B. bifidum* caused a reduction of total RNA content in G2 phase compared to the  
7 levels in Caco-2 cultures control (G1,  $70.9 \pm 2.9\%$ ; G2,  $28.8 \pm 1.7\%$ ).

8 **Pro-inflammatory cytokine production.** The activation of NF- $\kappa$ B and TNF $\alpha$   
9 production was induced in intestinal epithelial cell cultures by gliadin digestions non-  
10 inoculated with bifidobacteria (**Figure 2**). In all cases NF- $\kappa$ B activation was  
11 significantly ( $p < 0.05$ ) reduced when the gliadin digestions were inoculated with all  
12 bifidobacterial strains, compared to non inoculated digestions. TNF $\alpha$  production was  
13 reduced in cultures exposed to gliadin digestions inoculated with all bifidobacterial  
14 strains ( $p < 0.05$ ) and, especially, in those exposed to digests inoculated with *B. longum*,  
15 which were reduced to basal levels. In addition, IL-1 $\beta$  production was 2.7-fold higher  
16 ( $6.17 \pm 0.98$  ng/ml) in gliadin exposed culture supernatants than in controls ( $2.27 \pm 0.51$   
17 ng/ml). There was no statistically significant differences on IL-1 $\beta$  production ( $1.87$ - $2.34$   
18 ng/ml) in cultures exposed to gliadin digestions inoculated with bifidobacteria relative  
19 to the controls.

20 **mRNA expression of pro-inflammatory markers.** The reverse transcriptase-PCR  
21 analysis (**Figure 3**) revealed that the studied bifidobacterial strains reduced ( $p < 0.05$ ) the  
22 gliadin induced up-regulation of TNF $\alpha$  mRNA expression to different extent; the  
23 inhibitory effects of gliadins inoculated with *B. longum* were the highest. Furthermore,  
24 only inoculation of gliadin digestions with *B. longum* caused a down-regulation of NF-  
25  $\kappa$ B mRNA expression. According to these results together with those related to TNF $\alpha$   
26 production (Fig. 1), a post-transcriptional control of this pro-inflammatory biomarker  
27 seems to occur. In addition, an increased CXCR3 mRNA expression in cell cultures  
28 exposed to gliadin digestions non inoculated with bifidobacteria was noted.  
29 Interestingly, inoculation of gliadin digests with *B. longum* and *B. bifidum* lowered the  
30 CXCR3 mRNA expression to similar levels ( $p > 0.05$ ) as in controls.

31  
32

## 1        **DISCUSSION**

2        The gastrointestinal digestion of gliadins leads to the generation of peptides, which  
3        have been shown to exert cytotoxic and inflammatory effects on intestinal epithelial  
4        cells [Shan et al., 2005]. The concentration (0.25 mg/ml) of gliadin-derived peptides of  
5        the dialyzate samples used for the Caco-2 cells assays is achievable in the small  
6        intestine after consumption of a gluten-containing meal [Chartrand et al., 1997], and has  
7        been previously used in *in vitro* experiments on Caco-2 cell cultures as model of  
8        intestinal epithelia [Giovannini et al., 2000; 2003]. Herein, it has been demonstrated for  
9        the first time that the presence of the studied bifidobacterial strains during the intestinal  
10       digestion led to the generation of different gliadin peptide sequences *in vitro*, which  
11       could modify their toxic effects. In peptides derived from digestions non inoculated  
12       with bifidobacteria, amino acid sequences such as  $\alpha/\beta$ -Gld [122-141] and  $\alpha/\beta$ -Gld [158-  
13       164] similar as those proven to interact with the chemokine receptor CXCR3 [Lammers  
14       et al., 2008] have been identified. However, the aforementioned amino acid sequences  
15       were not detected in the gliadin digestions inoculated with bifidobacteria. This is  
16       particularly important since it has been suggested that gliadin-derived peptides stimulate  
17       enterocytes via the transmembrane G-protein-coupled chemokine CXCR3 receptor,  
18       which is involved in cytoskeleton rearrangement into inflamed tissues and the release of  
19       zonulin [Lammers et al., 2008]. In this context, the digestions inoculated with *B.*  
20       *bifidum* and *B. longum* did not up-regulate CXCR3 mRNA expression in contrast to the  
21       other digested gliadin samples, which could contribute to maintain the intestinal barrier  
22       integrity (Fig. 3).

23       Gliadin digestions, inoculated or not, with *B. animalis* and *B. bifidum* were  
24       cytotoxic for intestinal epithelial cells while not those inoculated with *B. longum*.  
25       However, the non-increased sub-G1 cell population in cell cultures challenged with  
26       every digestion, suggest that apoptosis processes are not involved in gliadin digests-  
27       mediated toxicity. Only, a reduction of total RNA content in G2 phase population was  
28       induced by gliadin digestions non inoculated and inoculated with *B. bifidum*, which  
29       could reflect alterations in the cell biology. Apoptosis has been suggested to be a major  
30       event that explains the villous atrophy in celiac disease [Moss et al., 1996] and, *in vitro*,  
31       wheat gliadins were shown to induce apoptosis of intestinal cells (Caco-2) [Giovannini  
32       et al., 2000; 2003] via an autocrine mechanism mediated by a receptor-mediated (Fas-  
33       Fas ligand) pathway [Giovannini et al., 2003]. In the present study, the use of confluent  
34       Caco-2 cultures, a lower protein concentration (0.25 mg/ml versus 0.5-1.5 mg/ml) to

1 challenge the cell cultures, and shorter exposure time (15h versus 48h) may be  
2 responsible for the differences observed in cell cycle progression between our results  
3 and those obtained by other authors [Giovannini et al., 2000; 2003]. It also should be  
4 taken into account that immature enterocytes present licking junctions causing an easier  
5 passage of gliadin-derived peptides through licking junctions producing stronger toxic  
6 effects than in mature cells.

7 In the present study, gliadin-derived peptides have been shown to trigger the  
8 activation of pro-inflammatory pathways (NF- $\kappa$ B) and the production of pro-  
9 inflammatory cytokines (TNF $\alpha$  and IL-1 $\beta$ ) (Fig. 2). The reduced NF- $\kappa$ B production in  
10 cultures exposed to digests of BSA may be explained by the significant down-regulation  
11 in nitric oxide synthase activity caused by albumin-derived glycosilation products  
12 [Rojas et al., 2000]. In contrast, NF- $\kappa$ B is known to be activated in small intestinal  
13 mucosa of CD patients [Chiara et al., 2003] and gluten peptides have been shown to up-  
14 regulate the expression of cytokines such as TNF $\alpha$  [Nilsen et al., 1998] and IL-1 $\beta$   
15 [Beckett et al., 1999], related to the innate immune response, in previous studies. The  
16 presence of bifidobacteria during intestinal digestion of gliadins reduced the ability of  
17 gliadin peptides to induce NF- $\kappa$ B (nuclear p65 subunit) and TNF $\alpha$  production,  
18 especially in the case of *B. longum*, and completely abolished the IL-1 $\beta$  production. Into  
19 cells, TNF $\alpha$  and IL-1 actions converge over the I $\kappa$ B kinase complex, which control the  
20 phosphorylation-regulated activation of NF- $\kappa$ B [Schmitz et al., 2001; Leeman and  
21 Gilmore, 2008]. However, it has been demonstrated that NF- $\kappa$ B is a negative regulator  
22 of IL-1 $\beta$  and that inhibition of I $\kappa$ B causes an increased IL-1 $\beta$  production in myeloid  
23 cells and neutrophils [Greten et al., 2007]. Thus, it seems likely that the use of probiotic  
24 bacteria could reduce the gliadin-induced NF- $\kappa$ B activation without disconnecting the  
25 NF- $\kappa$ B mediated regulatory effect on IL-1 $\beta$  production.

26 The extent of inhibitory effects produced by bifidobacteria on the pro-inflammatory  
27 response(s) to gliadins by Caco-2 cells seemed to depend on the strain considered. Of  
28 the tested strains, *B. longum* exerted the strongest inhibitory effects in both the NF- $\kappa$ B  
29 activation and TNF $\alpha$  production induced by gliadin-derived peptides in intestinal  
30 epithelial cells. The latter observations were correlated not only to the total proteins in  
31 dialyzates but also to the smaller molecular masses of peptides generated during *in vitro*  
32 digestion. These effects could have important consequences on the intestinal barrier  
33 function because TNF $\alpha$  increases tight junction dependent permeability, which

1 induction involves NF- $\kappa$ B activation [Ma et al., 2004]. The reduction of TNF $\alpha$   
2 production by gliadin digestions inoculated with *B. longum* might also have important  
3 physiological implications for CD since TNF $\alpha$  in conjunction with IL-1 $\beta$  are the most  
4 important cytokines involved in nitric oxide synthase (NOS) activation [Hoffman,  
5 2000]. NOS has been reported to act as a mediator to facilitate the interaction of  
6 intraepithelial lymphocytes and intestinal epithelial cells promoting tissue inflammation  
7 [Hoffman, 2000]. In addition, TNF $\alpha$  also has a positive effect on IL-8 production,  
8 which is a prototypic chemokine that attracts inflammatory cells such as neutrophils. A  
9 prolonged infiltration of neutrophils would perpetuate the inflammatory responses and  
10 contribute to cell damage, and epithelial barrier dysfunction.

11 In summary, the assayed bifidobacteria bacteria can cleave gliadin peptides during  
12 intestinal digestion, originating different peptide patterns that would reach the intestinal  
13 epithelia. In this way, bifidobacterial strains can inhibit the gliadin induced cytotoxic  
14 and pro-inflammatory responses in intestinal epithelial cells. Important inflammatory  
15 markers such as NF $\kappa$ B, TNF $\alpha$  and IL-1 $\beta$  were significantly reduced as a result of the  
16 proteolytic capacity of bifidobacteria on gliadin peptides. The reported data extend the  
17 spectrum of beneficial effects that probiotic bacteria might exert on intestinal epithelial  
18 cells function in CD and justify their possible evaluation in these patients.

19

## 20 **Acknowledgements**

21 This work was supported by grants AGL2008-01440/ALI and Consolider Fun-C-Food  
22 CSD2007-00063 from the Spanish Ministry of Science and Innovation (MICINN,  
23 Spain) and PIF08-010-4 from CSIC. J. M. Laparra has a postdoctoral contract of the  
24 programme “Juan de la Cierva” (MICINN, Spain).

## 1 **References**

- 2 Beckett CG, Dell'Olio D, Shidrawi RG, Rosen-Bronson S, Ciclitira PJ. 1999. Gluten-  
3 induced nitric oxide and pro-inflammatory cytokine release by cultured coeliac  
4 small intestinal biopsies. *Eur J Gastroenterol Hepatol* 5:529–535.
- 5 Borenfreund E, Puerner, J. 1985. Toxicity determined in vitro by morphological  
6 alterations and neutral red absorption. *Toxicol Lett.* 24:119-124.
- 7 Box GEP, Hunter NG, Hunter JS. 1978. *Statistics for Experimenters. An Introduction to*  
8 *Design, Data analysis and Model Building.* John Wiley & Sons, New York.
- 9 Chartrand LJ, Russo PA, Duhaine AG, Seidman EG. 1997. Wheat starch intolerance in  
10 patients with celiac disease. *J Am Diet Assoc.* 97:612-618.
- 11 Chiara, M, DeStefano D, Mele G, Fecarotta S, Greco L, Troncone R, Carnuccio R.  
12 2003. Nuclear factor kB is activated in small intestinal mucosa of celiac patients. *J*  
13 *Mol Med.* 81:373-379.
- 14 Ferguson LR, Shelling AN, Browning BL, Huebner C, Petermann I. 2007. Genes, diet  
15 and inflammatory bowel disease. *Mutat Res.* 622:70-83
- 16 Giovannini C, Matarrese P, Scazzocchio B, Vari R, D'archivio M, Straface E, Masella  
17 R, Malorni W, De Vincenzi M. 2003. Wheat gliadin induced apoptosis of  
18 intestinal cells via an autocrine mechanism involving Fas-Fas ligand pathway.  
19 *FEBS Lett.* 540:117-124.
- 20 Giovannini C, Sanchez M, Straface E, Scazzocchio B, Silano M, De Vincenzi M. 2000.  
21 Induction of apoptosis in Caco-2 cells by wheat gliadin peptides. *Toxicology*  
22 145:63-71.
- 23 Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Göktuna SI,  
24 Neuenhahn M, Fierer J, Paxian S, Rooijen NV, Xu Y, O'Cain T, Jaffee BB,  
25 Busch DH, Duyster J, Schmid R.M, Eckmann L, Karin M. 2007. NF-kappaB is a

1 negative regulator of IL-1beta secretion as revealed by genetic and  
2 pharmacological inhibition of IKKbeta. Cell. 130:918-931.

3 Hoffman RA. 2000. Intraepithelial lymphocytes coinduce nitric oxide synthase in  
4 intestinal epithelial cells. Am J Physiol: Gastrointest Liver Physiol 278: G886-  
5 G894.

6 Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, Rallabhandi P, Shea-  
7 donohue T, Tamiz A, Alkan S, Netzel-arnett S, Antalis T, Vogel SN, Fasano A.  
8 2008. Gliadin induces an increase in intestinal permeability and zonulin release  
9 by binding to the chemokine receptor CXCR3. Gastroenterology 135:194-204.

10 Laparra JM, Alegria A, Barberá R, Farré R. 2008. Antioxidant effect of casein  
11 phosphopeptides compared with fruit beverages supplemented with skimmed  
12 milk against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress in Caco-2 cells. Food Res Int. 41:773-  
13 779.

14 Laparra JM, Glahn RP, Miller DD. 2009. Assessing Potential Effects of Inulin and  
15 Probiotic Bacteria on Fe Availability from Common Beans (*Phaseolus vulgaris*  
16 L.) to Caco-2 Cells. J. Food Sci. 74:40-46.

17 Leeman JR, Gilmore TD. 2008. Alternative splicing in the NF-κB signaling pathway.  
18 Gene 423:97-107.

19 Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, Venäläinen J, Mäki M,  
20 Kaukinen K. 2008. Live probiotic *Bifidobacterium lactis* bacteria inhibit the toxic  
21 effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol.  
22 152: 552-558.

23 Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM. 2004.  
24 TNF-α-induced increase in intestinal epithelial tight junction permeability  
25 requires NF-κB activation. Am J Gastrointest Liver Physiol 286:G367-G376.

- 1 Medina M, De Palma G, Ribes-Koninckx C, Calabuig M and Sanz Y. 2008.  
2 Bifidobacterium strains suppress *in vitro* the pro-inflammatory milieu triggered  
3 by the large intestinal microbiota of coeliac patients. Journal of Inflammation  
4 (Lond). 5, 19 (doi:10.1186/1476-9255-5-19).
- 5 Moss SF, Attia L, Scholes JV, Walters JRF, Holt PR. 1996. Increased small intestinal  
6 apoptosis in celiac disease. Gut 39:811-817.
- 7 Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. 2007. Imbalance in the  
8 composition of the duodenal microbiota of children with celiac disease. J Med  
9 Microbiol. 56:1669-1674.
- 10 Nilsen EM, Jahnsen FL, Lundin KE, Johansen FE, Fausa O, Sollid LM, Jahnsen J, Scott  
11 H, Brandtzaeg P. 1998. Gluten induces an intestinal cytokine response strongly  
12 dominated by interferon gamma in patients with celiac disease. Gastroenterology  
13 115:551–563.
- 14 Rojas A, Romay S, González D, Herrera B, Delgado R, Otero K. 2000. Regulation of  
15 endothelial nitric oxide synthase expression by albumin-derived advanced  
16 glycosylation end products. Circ Res 86: E50-4.
- 17 Roselli M, Finamore A, Britti MS, Mengheri E. 2006. Probiotic bacteria  
18 *Bifidobacterium animalis* MB5 and *Lactobacillus rhamnosus* GG protect  
19 intestinal Caco-2 cells from the inflammation-associated response induced by  
20 enterotoxigenic *Escherichia coli* K88. Br J Nutr 95:1177–1184
- 21 Sanz Y, Sánchez E, Marzotto M, Calabuig M, Torriani S, Dellaglio F. 2007.  
22 Differences in faeca bacterial communities in celiac and healthy children as  
23 detected by PCR and denaturing gradient gel electrophoresis. FEMS Immunol  
24 Med Microbiol. 51:562-568.

- 1 Sanz Y. 2009. Novel perspectives in celiac disease therapy. *Mini Rev Med Chem.*  
2 9:359-67.
- 3 Schmitz ML, Bacher S, Kracht M. 2001. I $\kappa$ B-independent control of NF- $\kappa$ B activity by  
4 modulatory phosphorylations. *TRENDS Biochem Sci.* 26:186-190.
- 5 Shan L, Qiao SW, Arentz-Hansen H, Molberg Ø, Gray GM, Sollid LM, Khosla C.  
6 2005. Identification and analysis of multivalent proteolytically resistant peptides  
7 from gluten: implications for celiac sprue. *J Proteome Res* 4:1732-1741.
- 8 Thomas KE, Sapone A, Fasano A, Vogel SN. 2006. Gliadin Stimulation of Murine  
9 Macrophage Inflammatory Gene Expression and Intestinal Permeability Are  
10 MyD88-Dependent: Role of the Innate Immune Response in Celiac Disease. *J*  
11 *immunol* 176: 2512-2521.
- 12 Troncone R, Ivarsson A, Szajewska H, Mearins ML. 2008. Review article: future  
13 research on coeliac disease - a position report from the European multistakeholder  
14 platform on coeliac disease (CDEUSSA). *Aliment Pharmacol Ther.* 27:1030-  
15 1043.
- 16 Wieser H, Koehler P. 2008. The biochemical basis of celiac disease. *Cereal Chem.* 85:1-  
17 13.
- 18 Young SL, Simon MA, Baird MA, Tannock GW, Bibiloni R, Spencely K, Lane JM,  
19 Fitzharris P, Crane J, Town I, Addo-Yobo E, Murray CS, Woodcock A. 2004.  
20 Bifidobacterial species differentially affect expression of cell surface markers and  
21 cytokines of dendritic cells harvested from cord blood. *Clin Diagn Lab Immunol*  
22 11:686-690.

1 Figures' legend

2 **Figure 1.** Neutral red uptake percentages in Caco-2 cell cultures exposed to the  
3 dialyzable fraction (0.25 mg/mL) from digests of gliadins (Gld), inoculated or not with  
4 bifidobacteria. A digest of bovine serum albumin (BSA) was used as negative control of  
5 toxicity. Results are expressed as mean  $\pm$  standard deviation (n=5). Different superscript  
6 letters indicate statistically significant ( $P<0.05$ ) differences.

7

8 **Figure 2.** Nuclear factor kappa-B (NF- $\kappa$ B) and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ )  
9 production in Caco-2 cell cultures exposed to the dialyzable fraction from digests of  
10 gliadins (Gld), inoculated or not with bifidobacteria. A digest of bovine serum albumin  
11 (BSA) was used as negative control of cytokine-induced production. Results are  
12 expressed as mean  $\pm$  standard deviation (n=5). Different superscript letters for each  
13 biomarker indicate statistically significant ( $P<0.05$ ) differences.

14

15 **Figure 3.** mRNA expression of Pro-inflammatory biomarkers (TNF $\alpha$ , NF- $\kappa$ B, and  
16 chemokine CXCR3 receptor) in Caco-2 cell cultures exposed to the dialyzable fraction  
17 (0.25 mg/mL) from digests of gliadins (Gld), inoculated or not with bifidobacteria.  
18 Results are expressed as mean  $\pm$  standard deviation (n=5). Different superscript letters  
19 indicate statistically significant ( $P<0.05$ ) differences for each of the biomarkers  
20 analyzed.

21

22

**Table 1.** Gliadin-derived peptides in the dialyzates from different gastrointestinal digestions of gliadins, inoculated or not with bifidobacteria.

Sample	Peptide	Amino acid sequence	Observed m/z	Calculated m/z	Ion (m/z) selected for Ms(n) (charge)
Gliadins	$\alpha/\beta$ -Gld [158-164]	QVLQQST	802.9	803.4	802.9 (1)
	$\gamma$ -Gld [145-162]	VSSLWSIILPPSDCQVMR	2031.6	2032.4	2031.6 (1)
	$\alpha/\beta$ -Gld [122-141]	QQQQQQQILQQILQQILP	2460.6	2459.3	1230.3 (2)
	$\gamma$ -Gld [222-243]	QGIIQPQQPTQLEVFRSLVLQT	2489.3	2489.4	2489.3 (1)
	$\gamma$ -Gld [90-110]	QFPQSKQPQQPFPQPQQPQQ	2487.7	2488.2	2487.7 (1)
Gliadins + <i>B.animalis</i>	$\gamma$ -Gld [201-212]	QILVPLSQQQQV	1381.0	1381.6	1381.0 (1)
	$\omega$ -Gld [270-285]	SFPQQPQQPFPPTTK	1829.0	1830.0	1829.0 (1)
	$\omega$ -Gld [71-386]	QPQQPYPQQQPYGSSL	1845.6	1846.9	1845.6 (1)
	$\omega$ -Gld [310-330]	SQQSFLQPQPQQPQQPSILQP	2404.4	2405.6	1202.2 (2)
	$\alpha/\beta$ -Gld [233-269]	GFFQPSQNPQAQGSFQPQLPQFEAIRNLALQTLPA	4125.3	4127.56	1375.1 (3)

**Table 1.** Continuation.

<b>Sample</b>	<b>Peptide</b>	<b>Amino acid sequence</b>	<b>Observed m/z</b>	<b>Calculated m/z</b>	<b>Ion (m/z) selected for Ms(n) (charge)</b>
	$\omega$ -Gld [37-44]	FSHQQQPF	1018.5	1018.4	1018.5 (1)
	$\omega$ -Gld [310-318]	SQQSFLQPQ	1063.2	1063.1	1063.2 (1)
Gliadins + <i>B. bifidum</i>	$\alpha/\beta$ -Gld [52-62]	GQQQPFPPQQP	1252.3	1252.4	1252.3 (1)
	$\alpha/\beta$ -Gld [235-246]	FQPSQQNPQAQG	1329.5	1330.4	1329.5 (1)
	$\omega$ -Gld [358-375]	SQQPQQPFPPQQPHQPQQP	2125.0	2126.3	1062.5 (2)
	$\gamma$ -Gld [68-87]	QPQQPYPPQQPQQPFPPQTQQP	2390.2	2391.6	1195.1 (2)
	$\omega$ -Gld [62-68]	SQQPFPT	803.4	804.4	803.4 (1)
	$\omega$ -Gld [253-259]	QPQQLPQ	838.8	838.4	838.8 (1)
Gliadins + <i>B. longum</i>	$\gamma$ -Gld [91-97]	QPQQPFP	841.6	841.4	841.6 (1)
	$\alpha/\beta$ -Gld [195-202]	IILHQQQQ	1007.1	1007.6	1007.1 (1)
	$\gamma$ -Gld [123-132]	SLQQQLNPCK	1154.8	1158.6	577.0 (2)
	$\alpha/\beta$ -Gld [193-211]	QQPLSQVSFQQPQQQYPSG	2178.2	2178.0	1089.1 (2)
	$\omega$ -Gld [131-150]	LQPQQPFPPQQPQQPFQPQLP	2470.0	2468.3	1235.0 (2)